42
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bile acids in glucose metabolism in health and disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bile acids were recently shown to regulate glucose homeostasis through diverse mechanisms involving the host and its microbiome. Herein, Shapiro et al. discuss the impact of bile acids on normal and impaired glycemic responses, including potential therapeutic implications in treating hyperglycemia and diabetes.

          Abstract

          Bile acids (BAs) are cholesterol-derived metabolites that facilitate the intestinal absorption and transport of dietary lipids. Recently, BAs also emerged as pivotal signaling molecules controlling glucose, lipid, and energy metabolism by binding to the nuclear hormone farnesoid X receptor (FXR) and Takeda G protein receptor 5 (TGR5) in multiple organs, leading to regulation of intestinal incretin secretion, hepatic gluconeogenesis, glycogen synthesis, energy expenditure, inflammation, and gut microbiome configuration. Alterations in BA metabolism and signaling are associated with obesity and type 2 diabetes mellitus (T2DM), whereas treatment of T2DM patients with BA sequestrants, or bariatric surgery in morbidly obese patients, results in a significant improvement in glycemic response that is associated with changes in the BA profile and signaling. Herein, we review the roles of BAs in glucose metabolism in health and disease; highlight the limitations, unknowns, and challenges in understanding the impact of BAs on the glycemic response; and discuss how this knowledge may be harnessed to develop innovative therapeutic approaches for the treatment of hyperglycemia and diabetes.

          Related collections

          Most cited references85

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of a nuclear receptor for bile acids.

          Bile acids are essential for the solubilization and transport of dietary lipids and are the major products of cholesterol catabolism. Results presented here show that bile acids are physiological ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor. When bound to bile acids, FXR repressed transcription of the gene encoding cholesterol 7alpha-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis, and activated the gene encoding intestinal bile acid-binding protein, which is a candidate bile acid transporter. These results demonstrate a mechanism by which bile acids transcriptionally regulate their biosynthesis and enterohepatic transport.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pleiotropic roles of bile acids in metabolism.

            Enzymatic oxidation of cholesterol generates numerous distinct bile acids that function both as detergents that facilitate digestion and absorption of dietary lipids, and as hormones that activate four distinct receptors. Activation of these receptors alters gene expression in multiple tissues, leading to changes not only in bile acid metabolism but also in glucose homeostasis, lipid and lipoprotein metabolism, energy expenditure, intestinal motility and bacterial growth, inflammation, liver regeneration, and hepatocarcinogenesis. This review covers the roles of specific bile acids, synthetic agonists, and their cognate receptors in controlling these diverse functions, as well as their current use in treating human diseases. Copyright © 2013 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.

              Bile acids repress the transcription of cytochrome P450 7A1 (CYP7A1), which catalyzes the rate-limiting step in bile acid biosynthesis. Although bile acids activate the farnesoid X receptor (FXR), the mechanism underlying bile acid-mediated repression of CYP7A1 remained unclear. We have used a potent, nonsteroidal FXR ligand to show that FXR induces expression of small heterodimer partner 1 (SHP-1), an atypical member of the nuclear receptor family that lacks a DNA-binding domain. SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor that is known to regulate CYP7A1 expression positively. This bile acid-activated regulatory cascade provides a molecular basis for the coordinate suppression of CYP7A1 and other genes involved in bile acid biosynthesis.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                05 February 2018
                : 215
                : 2
                : 383-396
                Affiliations
                [1]Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
                Author notes
                Correspondence to Eran Elinav: eran.elinav@ 123456weizmann.ac.il
                [*]

                H. Shapiro, A.A. Kolodziejczyk, and D. Halstuch contributed equally to this paper.

                Author information
                http://orcid.org/0000-0002-2903-8884
                http://orcid.org/0000-0002-6331-5056
                Article
                20171965
                10.1084/jem.20171965
                5789421
                29339445
                9cdd1b92-d997-4fc1-842c-c52acb3c5318
                © 2018 Shapiro et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 30 October 2017
                : 11 December 2017
                : 19 December 2017
                Funding
                Funded by: Vera Rosenberg Schwartz Research Chair
                Funded by: European Molecular Biology Organization, DOI https://doi.org/10.13039/100004410;
                Funded by: Y. and R. Ungar
                Funded by: Gurwin Family Fund for Scientific Research
                Funded by: Leona M. and Harry B. Helmsley Charitable Trust, DOI https://doi.org/10.13039/100007028;
                Funded by: Crown Endowment Fund for Immunological Research
                Funded by: J. Gitlitz
                Funded by: L. Hershkovich
                Funded by: Benoziyo Endowment Fund for the Advancement of Science
                Funded by: Adelis Foundation
                Funded by: J.L. and V. Schwartz
                Funded by: A. and G. Markovitz
                Funded by: A. and C. Adelson
                Funded by: French National Center for Scientific Research, DOI https://doi.org/10.13039/501100007175;
                Funded by: D.L. Schwarz
                Funded by: Vera Rosenberg Schwartz Research Fellow Chair
                Funded by: L. Steinberg
                Funded by: J.N. Halpern
                Funded by: A. Edelheit
                Funded by: European Research Council, DOI https://doi.org/10.13039/100010663;
                Funded by: Marie Curie Integration
                Funded by: German-Israeli Foundation for Scientific Research and Development, DOI https://doi.org/10.13039/501100001736;
                Funded by: Israel Science Foundation, DOI https://doi.org/10.13039/501100003977;
                Funded by: Minerva Foundation, DOI https://doi.org/10.13039/501100001658;
                Funded by: Helmholtz Foundation
                Funded by: European Foundation for the Study of Diabetes, DOI https://doi.org/10.13039/501100001648;
                Funded by: Sir Marc and Lady Tania Feldmann Professorial Chair in Immunology
                Funded by: Canadian Institute for Advanced Research, DOI https://doi.org/10.13039/100007631;
                Funded by: Bill and Melinda Gates Foundation, DOI https://doi.org/10.13039/100000865;
                Funded by: Howard Hughes Medical Institute, DOI https://doi.org/10.13039/100000011;
                Categories
                Reviews
                Review
                321

                Medicine
                Medicine

                Comments

                Comment on this article